Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Zdravljenje bolnikov s ploščatoceličnim karcinomom glave in vratu z obsevanjem in cetuksimabom
Avtorji:Strojan, Primož (Avtor)
Zakotnik, Branko (Avtor)
Jezik:Slovenski jezik
Tipologija:1.04 - Strokovni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Leto izida:2008
UDK:616-006
ISSN pri članku:1408-1741
OceCobissID:65324032 Povezava se odpre v novem oknu
URN:URN:NBN:SI:doc-PMPB2DPT
COBISS_ID:701051 Povezava se odpre v novem oknu
Opombe:BSDOCID143366;
Število ogledov:1312
Število prenosov:252
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (385,52 KB)
 
Nadgradivo:Onkologija
Onkološki inštitut
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:by Authors
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:31.08.2018

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck with Concomitant Irradiation and Cetuximab
Povzetek:Contemporary management of locally and regionally advanced squamous cell carcinoma of the head and neck combines simultaneous application of radiotherapy and chemotherapy. With more comprehensive understanding of radiobiological principles of radiotherapy and recent developments in biological drug modeling and technology, more room was provided for improving some other areas of treatment. One of the new promising strategies in the treatment of head and neck carcinomas is the inhibition of epidermal growth factor receptor (EGFR) signaling using anti-EGFR monoclonal antibodies (e.g. cetuximab, Erbitux). In this article, we present the first two patients treated at the Institute of Oncology Ljubljana with the combination of irradiation and cetuximab and discuss theoretical background for the new treatment regime and other possible therapeutic indications for cetuximab in head and neck oncology.

Arhiv

niGradiv

Nazaj